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Abstract: Cisplatin (CDDP) plus radiotherapy (RT) has been used to
treat advanced laryngeal squamous cell carcinoma (LSCC) patients.
Single nucleotide polymorphisms (SNPs) may be responsible for differ-
ences in chemo/radiosensitivity and side effects in those patients. We
reported an advanced LSCC patient, who obtained durable complete
response and unexpected pronounced toxicity during CDDP and RT,
possibly due to SNPs in genes that modulate the effects of this
therapeutic modality. Case presentation: A 30-year-old man with
advanced LSCC obtained durable complete response and severe alo-
pecia and pancytopenia after standard and reduced doses of CDDP and
RT. Analyses of SNPs revealed that the patient presented GSTT1
deletion, variant MSH3 1045ThrThr, wild GSTP1 105IleIle, and wild
BAX -248GG genotypes, which were previously described in association
with abnormal detoxification, DNA repair, and damaged cell apoptosis,
respectively. Seven other advanced LSCC patients with GSTT1 gene,
MSH3 AlaAla or AlaThr, GSTP1 IleVal or ValVal, and BAX GA or AA
genotypes served as controls of the study. Only 1 control presented
complete response; the other 6 controls obtained partial response ofo Pincinato, MSc, l, MD, PhD,
Carmen Silvia Passos Lima, MD, PhD
than the median value obtained in controls, suggesting a higher amount
of intracellular CDDP in the reported case.
The data suggest, for the first time, that inherited abnormalities in
intracellular detoxification of CDDP, DNA repair of lesions induced by
CDDP and RT, and damaged cell apoptosis may alter treatment
response and toxicity in LSCC, but should be confirmed by large
pharmacogenomic studies.
(Medicine 94(16):e578)
Abbreviations: CDDP = cisplatin, HNSCC = head and neck
squamous cell carcinoma, LSCC = laryngeal squamous cell
carcinoma, RT = radiotherapy, SNP = single nucleotide poly-
morphism.
INTRODUCTION
C isplatin (CDDP) plus radiotherapy (RT) has been used fororgan preservation in advanced laryngeal squamous cell
carcinoma (LSCC).1
Complete and partial responses were identified in approxi-
mately 90% and 10% of patients with stage III or IV LSCC
treated with CDDP and RT, respectively, which persisted for
2 years in about 80% of cases.1 Grade 3 or 4 anemia, leucopenia,
or thrombocytopenia attributed to treatment was seen in 47% of
treated patients.1 To the best of our knowledge, there are no
descriptions in the literature regarding pancytopenia after stan-
dard doses of CDDP, and alopecia is a rare event in treated
patients.2
CDDP develops covalent bifunctional DNA adducts with
cellular DNA. CDDP-DNA adducts are repaired particularly by
nucleotide excision pathways, and when the repair of DNA
lesions are not possible, apoptosis is activated, leading damaged
cells to death. Similarly, ionizing radiation induces damage to
DNA directly by action of photons and/or indirectly by liber-
ation of free radicals, which induces damaged cell apoptosis
when not adequately repaired, particularly by mismatch and
base excision pathways.
Variations in tumor sensitivity to CDDP and RT, as well as
side effects of therapeutic modalities have been attributed to
distinct activities of proteins, encoded by single nucleotide
polymorphisms (SNPs) in different genes. The main SNPs
potentially involved in modulation of effects of this treatment
are presented in Table 1.T14 genotypes, enrolled in detoxifica-
and Asp312Asn,3 MSH3 Ala1045Thr,5
SNPs, enrolled in DNA repair, and P53
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TABLE 1. Polymorphisms Involved in Detoxification of Cisplatin and Mechanisms of DNA Repair and Apoptosis Pathway
Polymorphism Reference Protein Function Patient Genotype
Detoxification
GSTM1 Deletion: decrease in detoxification Present
GSTT1 Deletion: decrease in detoxification Null
GSTP1 Ile105Val rs1695 Val: decrease in detoxification IleIle
Nucleotide excision repair
XPC Lys939Gln rs2228001 Gln: decrease in repair capacity LysGln
XPD Lys751Gln rs13181 Gln: decrease in repair capacity LysGln
XPD Asp312Asn rs1799793 Asn: decrease in repair capacity AspAsn
ERCC1 C118T rs11615 T: decrease in repair capacity CT
Mismatch repair
MSH3 Ala1045Thr rs26279 Thr: decrease in repair capacity ThrThr
EXO1 K589E rs1047840 A: decrease in repair capacity GA
Base excision repair
XRCC1 Arg399Gln rs25487 Gln: decrease in repair capacity ArgArg
Apoptosis intrinsic pathway
P53 Arg72Pro rs1042522 Arg: increase in apoptosis induction ArgPro
GSTP1 Ile105Val rs1695 Ile: increase in apoptosis induction IleIle
BAX G-248A rs4645878 G: increase in apoptosis induction GG
CASP3 A-928G rs12108497 A: increase in apoptosis induction AG
Genotypes were identified from DNA of peripheral blood by multiplex-polymerase chain reaction or polymerase chain reaction and enzymatic
of c
Lopes-Aguiar et al Medicine  Volume 94, Number 16, April 2015Arg72Pro,3 andGSTP1 Ile105Val3,8 SNPs, enrolled in damaged
cell apoptosis, were associated with variable response, toxicity,
progression-free survival, and overall survival of patients with
different tumors treated with platinum-based chemotherapy
with or without RT; however, only few studies were conducted
in head and neck SCC (HNSCC) patients.4,6–8
We report a man with advanced LSCC, with concurrent
inherited abnormalities in CDDP and RT metabolism, which
seemed to confer sensitivity to treatment even though with
pronounced side effects.
CASE REPORT
A 30-year-old man, drinker and smoker, was seen as an
outpatient at the University Hospital in October 2011 with
hoarseness for the past 4 months. A vegetative lesion occupying
anterior 2/3 of right vocal cord and anterior third of left vocal
cord was detected during laryngoscopy. Computed tomography
of neck evidenced uptake vegetating lesion in the right vocal
cord and bilateral lymph node metastasis (level 2) (15.0 and
23.2mm). After histological evaluation of tumor fragment, the
diagnosis of moderately differentiated LSCC was established.
The tumor was staged as IVa (T2N2cM0) according to the
American Joint Committee on Cancer Staging criteria. The
human papillomavirus type 16 was negative in tumor.
The patient entered into a treatment protocol consisting of
‘‘in bolus’’ intravenous CDDP at dose of 100mg/m2 on days 1,
22, and 43, and concurrent single daily fractionated radiation
(2Gy/day). As antiemetic protocol, he received intravenous
24mg ondansetron and 20mg dexamethasone, before CDDP
infusion, as well as oral 8mg dexamethasone (every 12 hours)
and 10mg metoclopramida (every 6 hours) during 3 days after
digestion, and were confirmed in independent experiments with 100%each CDDP infusion. On day 19, after developing grade 2
alopecia, fever, severe pancytopenia (leukocytes 0.7 103/
mm3, neutrophils 0.0 103/mm3, hemoglobin 7.8 g/dL,
2 | www.md-journal.comthrombocytes 14.0 103/mm3), the patient received blood trans-
fusion, intravenous 500mg vancomycin (every 6 hours), 1 g
cefepime (every 8 hours), and subcutaneous 300mg of granulo-
cyte-colony-stimulating factor (once a day). After hematologic
recovery, intravenousCDDP30mg/m2was administered on days
33, 40, and 47. On day 54, the patient developed another episode
of fever, pancytopenia (leukocytes 0.5 103/mm3, neutrophils
0.0 103/mm3, hemoglobin 7.9 g/dL, thrombocytes 28.0 103/
mm3), requiring supportive treatment. After this episode, the
patient received exclusive RT. Hematologic recovery was seen
only on day 132 (Figure 1).
The computed tomography of neck evidenced complete
remission of LSCC in April 2012, according to the Response
Evaluation Criteria in Solid Tumors, which was maintained
until the last follow-up in January 2015 (34 months of duration).
The patient presented GSTT1 deletion, variant MSH3
ThrThr genotype, and wild GSTP1 IleIle and BAX GG geno-
types (Table 1).
All LSCC outpatients with clinical and tumor aspects
similar to those seen in the reported case, and with GSTT1
gene, MSH3 AlaAla or AlaThr, GSTP1 IleVal or ValVal, and
BAX GA or AA genotypes seen in our service during the last 3
years (2012–2014) served as controls of the study (n¼ 7). All
controls were treated with intravenous CDDP (100mg/m2 on
days 1, 22, and 43) and concurrent single daily fractionated
radiation (2Gy/day). Only 1 control presented complete
response; the remaining 6 controls obtained partial response
of short duration. Four and 3 controls presented grade 1 or 2 and
grade 3 anemia or leucopenia analyzed by the National Cancer
Institute criteria during treatment, respectively. Alopecia was
not seen in any control of the study. Surgical resection of
residual tumors was not performed due to locoregional irresist-
oncordance. DNA¼ deoxyribonucleic acid.ibility or patient refusal. At the end of the study, 5 out of
7 controls died due to tumor effects. The CDDP level was
measured by high-performance liquid chromatography in
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 1. Leukocytes, neutrophils, hemoglobin, and thrombocytes values before treatment (baseline on day 0) and after treatment with
cisplatin-based chemotherapy (first cycle dose: 100mg/m2 and second cycle dose: 30mg/m2 during 3-week applications) concomitant
with radiotherapy. During the first cycle, on day 19, and during the second cycle, on day 54, severe pancytopenia occurred and required
ran
eco
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the first intravenous administration of CDDP. The CDDP level
in urine of the reported patient (2.20mg/m2) was lower than the
median level of CDDP found in urine of controls (9.90mg/m2;
variation: 3.67–26.00; P¼ 0.01, 1-sample exact Wilcoxon
signed rank test) (Table 2).
DISCUSSION
In this case report, an outpatient with advanced LSCC
treated with CDDP and RT presented durable complete
response, and unexpected severe pancytopenia and alopecia.
In fact, CDDP and RT may determine complete response in
blood transfusion and antibiotic, as well as the administration of g
occurred on day 26 (after the first cycle of CDDP) and final r
CDDP¼ cisplatin.HNSCC patients, and it may be even longer than 2 years.1
However, alopecia grade 2 is a rare event,2 and severe pancy-
topenia was reported only in cancer patients treated with CDDP
TABLE 2. Clinical Features, Tumoral Aspects, and Urinary Cisp
Carcinoma
Tumor Resp
Case
Age
(y) Gender
KPS
(%)
Histological
Grade
TNM
Stage Type
Dur
to
De
1 30 Male 90 MD IVa Complete
2 44 Male 90 MD III Partial
3 57 Male 90 MD IVb Partial
4 51 Male 90 MD III Partial
5 58 Male 90 MD IVa Partial
6 48 Male 90 MD III Complete
7 57 Male 90 MD III Partial
8 64 Male 90 MD IVb NE
Case 1 is the reported case and cases 2 to 8 are the controls of study. CD
performance status, MD¼moderately-differentiated, NE¼ not evaluated, b
The major degree of anemia or leukopenia found in each patient and for
presented in table.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.overdose.9 To the best of our knowledge, there are no descrip-
tions in the literature regarding pancytopenia after standard
doses of CDDP.
Thus, we checked whether inherited abnormalities in
intracellular detoxification of CDDP, DNA repair, and damaged
cell apoptosis could constitute a plausible explanation for the
uncommon findings seen in the reported patient. SNP analyses
revealed that the patient presented deletion of GSTT1, associ-
ated with decreased detoxification of CDDP and RT products,3
variant MSH3 ThrThr genotype, associated with possible
decrease in DNA repair by mismatch pathaway,10 and wild
GSTP1 IleIle3,8 and BAXGG genotype, associated with increase
in apoptosis induction by intrinsic pathway.11
ulocyte-colony-stimulating factor (G-CSF). Hematologic recovery
very occurred on day 132 (after the second cycle of CDDP).No association between homozygous deletion of GSTT1
and response rate in HNSCC,4 but radiosensitivity associated
withMSH3 Ala allele in breast cancer patients,5 was previously
latin Excretion in Patients With Laryngeal Squamous Cell
onse
ation or Time
Progression/
ath (months)
Hematologic
Toxicity

Urinary
CDDP
(mg/m2)
Outcome
Endpoint
34.0 Grade 4 2.2 Alive without disease
5.0 Grade 1 3.7 Alive with disease
4.0 Grade 3 17.0 Death
1.0 Grade 3 10.9 Death
6.0 Grade 2 6.0 Death
10.0 Grade 1 26.0 Alive without disease
6.0 Grade 3 9.0 Death
0.3 Grade 2 9.9 Death
DP¼ cisplatin, TNM¼ tumor, node and metastasis, KPS¼Karnofsky
ecause the patient evolved to death at the end of treatment.
anemia, leucopenia and thrombocytopenia found in the reported case are
www.md-journal.com | 3
described during treatment using CDDP-based chemotherapy
and RT. The wild IleIle genotype of GSTP1 Ile105Val SNP
conferred higher response and longer survival to ovarian cancer
patients treated with CDDP-based chemotherapy,3 but not to
HNSCC patients treated with RT and CDDP.8 Severe neutro-
penia was more frequent in ovarian cancer patients with AspAsn
and ArgArg genotypes of XPD Asp312Asn and XRCC1
Arg399Gln SNPs, respectively, who were treated with standard
dose of CDDP.3 HNSCC patients with Gln allele of XRCC1
Arg399Gln SNP were under high risk of mucositis if treated
with RT.7 Moreover, variant ThrThr genotype of MSH3
Ala1045Thr SNP was associated with severe radiation derma-
titis in breast cancer patients.5
Previous descriptions, even incipient, indicate that SNPs
with activity in intracellular detoxification, DNA repair, and/or
apoptosis of damage cells may alter response and toxicity to
therapy, and prognosis of cancer patients treated with CDDP-
based chemotherapy and RT. Facing these descriptions and our
findings, we hypothesized that homozygous deletion of GSTT1
gene decreased intracellular detoxification of CDDP,12 variant
Thr allele ofMSH3 Ala1045Thr SNP decreased DNA repair by
mismatch pathway13 and wild Ile14 and G11 alleles of GSTP1
Ile105Val and BAX G-248A SNPs, respectively, increased
apoptosis of tumor and normal cells by intrinsic pathway,
determining durable complete response, pronounced pancyto-
penia, and total alopecia in the reported case, while the remain-
ing genotypes of the genes had the opposite effects on the other
7 patients enrolled in the study.
We also found in study that CDDP level in urine of the
reported casewas lower than levels found in urine of controls. It
is already well known that pharmacokinetic studies of CDDP
are usually carried out in blood samples collected between 1
and 18 hours after CDDP infusion.15,16 However, since out-
patients were enrolled in this study, only 12-hour urine was
available for CDDP analysis. Lanjwani et al (2006)16 found a
good correlation between levels of CDDP in blood and urine
samples, and postulated that both methods may be used in
pharmacokinetic studies of CDDP. Thus, we believe that
urinary CDDP levels found in our study might reflect the
plasma concentration of the agent in our patients. Conversely,
correlation between CDDP concentration in plasma and
formation of CDDP-DNA adducts in leukocytes of patients
with cancer is controversial.17,18 Since CDDP urinary concen-
tration may reflect CDDP plasma levels, and CDDP plasma
concentration may be correlated with CDDP-DNA adducts in
cells, we hypothesized that low urinary CDDP level in urine
of the reported case might be associated with retention of
CDDP in normal and tumor cells in our patients, with formation
of CDDP-DNA adducts and consequent good response to
therapy and pronounced toxicity, while high concentration
of CDDP in urine of controls might be correlated with opposite
findings.
Our data suggest, for the first time, that homozygous
GSTT1 deletion, MSH3 Ala1045Thr, GSTP1 Ile105Val, and
BAX G-248A SNPs can act together and modulate the response
rate and toxicity of CDDP associated with RT in the patient with
LSCC. However, we believe that large studies in pharmacoge-
nomics are required to clearly define the roles of the above-
mentioned SNPs on modulation of CDDP and RT effects in
those patients.
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